BMRN:NASDAQ
Biomarin Pharmaceutical Inc
55,20 $
arrow_downward
-1,81%(-1,02) 1D
55,35 $
arrow_upward
+0,27% (+0,15)todayPre-market
Closed: 7 қаз., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
56,05 $
High
56,60 $
Low
54,76 $
Mkt. cap
10,69 млрд
Avg. vol.
2,01 млн
Volume
588,00
P/E ratio
148,82
52-wk high
70,98 $
52-wk low
49,26 $
EPS
0,37 $
Beta
0,22
Shares outstanding
193,57 млн
No. of employees
3 мың
Open
56,05 $
High
56,60 $
Low
54,76 $
Mkt. cap
10,69 млрд
Avg. vol.
2,01 млн
Volume
588,00
P/E ratio
148,82
52-wk high
70,98 $
52-wk low
49,26 $
EPS
0,37 $
Beta
0,22
Shares outstanding
193,57 млн
No. of employees
3 мың
News stories
From web sources and news partners
Zacks
·
18 сағат бұрын
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
AD HOC NEWS
·
1 күн бұрын
BioMarin flags USD 283 million charge. BioMarin stock loses 1.83 percent.
TradingView
·
1 күн бұрын
BioMarin Q3 financial results to see IPR&D expense impact of $283M
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3,22 мың
Foundedнау. 1997
HeadquartersSan Rafael, Калифорния, Америка Құрама Штаттары
Sector-
Websitebiomarin.com